|
|
|
(Journal Article): Cell replacement therapy for type 1 diabetes.
Efrat S (Dept of Human Genetics and Molecular Medicine, Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel,
sefrat(at)post.tau.ac.il
)
IN:
Trends Mol Med
2002; 8(7):334-339
Impact Factor(s) of Trends Mol Med: 7.497 (2004), 9.848 (2003), 7.162 (2002)
Fulltext:
HTML
PDF
ABSTRACT: Replacement of the insulin-producing pancreatic islet beta cells represents the ultimate treatment for type 1 diabetes. Recent advances in islet transplantation underscore the urgent need for developing alternatives to human tissue donors, which are scarce. Two possible approaches are the expansion of differentiated beta cells by reversible immortalization and the generation of insulin-producing cells from embryonic or adult stem cells. It is possible that new insights into endocrine pancreas development will ultimately lead to manipulation of progenitor-cell fate towards the beta-cell phenotype of insulin production, storage and regulated secretion. Both allogeneic and autologous surrogate beta cells are likely to require protection from recurring autoimmunity. This protection might take the form of tolerization, cell encapsulation, or cell engineering with immunoprotective genes. If successful, these approaches could lead to widespread cell replacement therapy for type 1 diabetes.
TYPE OF PUBLICATION: Original article
Articles citing this article:
|
Respond
on this Journal Article!
Hint: Your Response should directly apply to Cell replacement therapy for type 1 diabetes..
Please check, if this context applies best to your contribution. Otherwise click HERE to change to the appropriate
subject area. The actual subject area is Progenitors.
|
|
|
|
|
